Guggenheim initiated coverage of ProKidney with a Buy rating and $6 price target. Despite recent advances in the treatment of chronic kidney disease, there remains a significant unmet medical need for additional therapeutic options, the analyst tells investors in a research note. Based on the early Phase 2 data from ProKidney’s innovative cell therapy approach, Guggenheim is optimistic that rilparencel will be a viable option for a subset of those patients to slow the progression of their kidney disease and delay the need for dialysis. Additional data from the Phase 2 REGEN-007 trial in the first half of 2025 2025 and more insights on rilparencel’s mechanism of action in the second half of 2025 “should help to derisk the story,” contends the firm.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- ProKidney price target lowered to $3 from $4 at BofA
- ProKidney: Investor Update and Phase 3 Program Progress
- ProKidney to discontinue PROACT 2, focus resources on PROACT 1
- ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
- ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue